IHAM
VKTX icon

Integral Health Asset Management’s Viking Therapeutics VKTX Stock Holding History

Integral Health Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$5.3M – 89
2025
Q2 		$5.3M Hold
200,000
– – 0.49% 53
2025
Q1 		$4.83M Buy
+200,000
New +$6.32M 0.51% 53
2024
Q4 		– Sell
-250,000
Closed -$15.8M – 100
2024
Q3 		$15.8M Hold
250,000
– – 1.78% 17
2024
Q2 		$13.3M Buy
+250,000
New +$16.4M 1.26% 26

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Integral Health Asset Management's VKTX Position: Q2 2026 in Review

Integral Health Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 250,000 shares — an estimated $8.13M sold.

Integral Health Asset Management first reported a position in VKTX in Q4 2022 and held it in 10 quarters. The position peaked at $36.9M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Integral Health Asset Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Integral Health Asset Management sold 250,000 Viking Therapeutics shares in Q2 2026, an estimated $8.13M.
  • Integral Health Asset Management first reported a position in Viking Therapeutics in Q4 2022 and held it in 10 quarters.
  • Integral Health Asset Management's Viking Therapeutics position peaked at $36.9M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.